JP2006509743A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006509743A5 JP2006509743A5 JP2004550274A JP2004550274A JP2006509743A5 JP 2006509743 A5 JP2006509743 A5 JP 2006509743A5 JP 2004550274 A JP2004550274 A JP 2004550274A JP 2004550274 A JP2004550274 A JP 2004550274A JP 2006509743 A5 JP2006509743 A5 JP 2006509743A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- pharmaceutical composition
- alkyl
- phenyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims description 48
- -1 1-oxo-1,3-dihydro-isoindol-2-yl Chemical group 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000001475 halogen functional group Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000004442 acylamino group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 125000006277 halobenzyl group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 208000002780 macular degeneration Diseases 0.000 claims 10
- 102000004127 Cytokines Human genes 0.000 claims 9
- 108090000695 Cytokines Proteins 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000007726 management method Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 2
- 229940080818 propionamide Drugs 0.000 claims 2
- 239000000790 retinal pigment Substances 0.000 claims 2
- 238000011477 surgical intervention Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- GZRGLZWHIFBBLS-UHFFFAOYSA-N 4-amino-2,3-dihydroisoindol-1-one Chemical compound NC1=CC=CC2=C1CNC2=O GZRGLZWHIFBBLS-UHFFFAOYSA-N 0.000 claims 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 206010023126 Jaundice Diseases 0.000 claims 1
- 208000035719 Maculopathy Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 1
- 241001483078 Phyto Species 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 208000027073 Stargardt disease Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 235000013405 beer Nutrition 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 238000002647 laser therapy Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 239000003504 photosensitizing agent Substances 0.000 claims 1
- 238000001126 phototherapy Methods 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 125000002345 steroid group Chemical group 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 claims 1
- 229960003895 verteporfin Drugs 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42290002P | 2002-10-31 | 2002-10-31 | |
| PCT/US2003/034535 WO2004041181A2 (en) | 2002-10-31 | 2003-10-31 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006509743A JP2006509743A (ja) | 2006-03-23 |
| JP2006509743A5 true JP2006509743A5 (OSRAM) | 2006-07-20 |
Family
ID=32312567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004550274A Pending JP2006509743A (ja) | 2002-10-31 | 2003-10-31 | 黄斑変性の治療および管理のための選択的サイトカイン阻害薬の使用方法およびそれを含む組成物 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1567148A4 (OSRAM) |
| JP (1) | JP2006509743A (OSRAM) |
| KR (1) | KR20050062649A (OSRAM) |
| CN (1) | CN1731997A (OSRAM) |
| AU (1) | AU2003285107B2 (OSRAM) |
| BR (1) | BR0315889A (OSRAM) |
| CA (1) | CA2504263A1 (OSRAM) |
| MX (1) | MXPA05004486A (OSRAM) |
| NZ (1) | NZ540185A (OSRAM) |
| TW (1) | TW200418455A (OSRAM) |
| WO (1) | WO2004041181A2 (OSRAM) |
| ZA (1) | ZA200503468B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| CN103402980B (zh) * | 2011-01-10 | 2016-06-29 | 细胞基因公司 | 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物 |
| KR101908330B1 (ko) | 2017-02-17 | 2018-10-16 | 인제대학교 산학협력단 | 신규 항-vegf 항체 및 이를 유효성분으로 포함하는 나이관련 황반변성 예방 또는 치료용 조성물 |
| IL283127B1 (en) * | 2018-11-14 | 2026-02-01 | Smilebiotek Zhuhai Ltd | Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders |
| JP7443361B2 (ja) * | 2018-12-03 | 2024-03-05 | 珠海岐微生物科技有限公司 | 加齢黄斑変性症の治療方法 |
| JP7761924B2 (ja) * | 2021-06-24 | 2025-10-29 | 山陽色素株式会社 | 赤色顔料分散体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US577589A (en) * | 1897-02-23 | Valve for explosive-engines | ||
| US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5770589A (en) * | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| JP2001511448A (ja) * | 1997-07-31 | 2001-08-14 | セルジーン コーポレイション | 置換アルカノヒドロキサム酸およびＴＮＦαレベルの減少方法 |
| AU749356B2 (en) * | 1998-05-11 | 2002-06-27 | Children's Medical Center Corporation | Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| JP2000159761A (ja) * | 1998-11-30 | 2000-06-13 | Yoshio Takeuchi | フルオロサリドマイド |
| US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| MXPA04010267A (es) * | 2002-04-19 | 2005-02-03 | Smithkline Beecham Corp | Compuestos novedosos. |
| WO2003097040A1 (en) * | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| US7842691B2 (en) * | 2002-10-15 | 2010-11-30 | Celgene Corporation | Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide |
-
2003
- 2003-10-31 EP EP03779423A patent/EP1567148A4/en not_active Withdrawn
- 2003-10-31 BR BR0315889-6A patent/BR0315889A/pt not_active IP Right Cessation
- 2003-10-31 CA CA002504263A patent/CA2504263A1/en not_active Abandoned
- 2003-10-31 NZ NZ540185A patent/NZ540185A/en not_active IP Right Cessation
- 2003-10-31 WO PCT/US2003/034535 patent/WO2004041181A2/en not_active Ceased
- 2003-10-31 ZA ZA200503468A patent/ZA200503468B/en unknown
- 2003-10-31 JP JP2004550274A patent/JP2006509743A/ja active Pending
- 2003-10-31 AU AU2003285107A patent/AU2003285107B2/en not_active Ceased
- 2003-10-31 KR KR1020057007608A patent/KR20050062649A/ko not_active Ceased
- 2003-10-31 MX MXPA05004486A patent/MXPA05004486A/es active IP Right Grant
- 2003-10-31 CN CNA2003801080906A patent/CN1731997A/zh active Pending
- 2003-10-31 TW TW092130486A patent/TW200418455A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11065236B2 (en) | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | |
| JP2001517639A (ja) | 鼻炎／結膜炎および感冒、感冒に似た症状および／または流行性感冒の症状を局所的に治療するための、鎮静作用を有しない抗ヒスタミンおよびα−アドレナリン作動薬を含む組合せ物の使用 | |
| JP2011506455A (ja) | 癌を処置するための治療薬の組み合わせ剤 | |
| CN1277553A (zh) | 血管生成促进剂和血管生成增效剂 | |
| JP7222042B2 (ja) | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 | |
| JPWO2019177117A1 (ja) | 咳嗽の治療のための医薬 | |
| JP2000514402A (ja) | Ｖｅｇｆに関連する目の病気に関する治療処置 | |
| JP2006510606A5 (OSRAM) | ||
| WO2012060397A1 (ja) | 帯状疱疹関連痛の急性期疼痛の予防又は治療剤 | |
| US6420428B1 (en) | Treatment and prevention of hepatic disorders | |
| CN1859913A (zh) | 改善肾功能损伤个体多尿症的方法 | |
| ES2215327T3 (es) | Composicion de medicamento inmunomodulador. | |
| TW200418455A (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | |
| JP2007509932A5 (OSRAM) | ||
| US20030212050A1 (en) | Prophylactic treatment of migraine | |
| JPS6296424A (ja) | 改良された抗炎症組成物 | |
| CN1917865A (zh) | 有机化合物的组合 | |
| JP2009143929A (ja) | 睡眠障害の予防・治療剤 | |
| JP2003503343A (ja) | 治療剤 | |
| JP2012506404A (ja) | 片頭痛処置用組み合わせ剤 | |
| WO2021203001A1 (en) | Method of treating patients infected with a viral infection with an inhibitor of small ubiquitin like modifier activating enzyme | |
| JP2002514208A (ja) | 痴呆の治療及び予防におけるシクロオキシゲナーゼ−２阻害剤の使用方法 | |
| WO2001066110A2 (en) | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS | |
| JPH07508997A (ja) | 抗ウイルス剤の組み合わせ | |
| JPH1192381A (ja) | 心不全の予防・治療剤 |